Regulation of complement-dependent cytotoxicity by TGF-β-induced epithelial-mesenchymal transition

Oncogene

Volumn 35, Issue 15, 2016, Pages 1888-1898

  Goswami, M T ^a   Reka, A K ^a   Kurapati, H ^a   Kaza, V ^a   Chen, J ^a   Standiford, T J ^a   Keshamouni, V G ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD59 ANTIGEN; CETUXIMAB; COMPLEMENT INHIBITOR; COMPLEMENT MEMBRANE ATTACK COMPLEX; DECAY ACCELERATING FACTOR; NERVE CELL ADHESION MOLECULE; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; VIMENTIN; CD59 PROTEIN, HUMAN; LYST PROTEIN, MOUSE; MESSENGER RNA; PROTEIN; RNA; SMAD3 PROTEIN, HUMAN; SMALL INTERFERING RNA; TRANSCRIPTOME; TUMOR PROTEIN;

A549 CELL LINE; ACTIN FILAMENT; ARTICLE; CELL STRUCTURE; CHROMATIN IMMUNOPRECIPITATION; COMPLEMENT ACTIVATION; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; CYTOLYSIS; EPITHELIAL MESENCHYMAL TRANSITION; EXPERIMENTAL METASTASIS; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNE EVASION; IMMUNOSURVEILLANCE; LUNG TUMOR; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR MICROENVIRONMENT; ADENOCARCINOMA; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CYTOTOXICITY; DRUG SCREENING; GENE EXPRESSION REGULATION; GENE VECTOR; GENETICS; IMMUNOLOGY; MALE; MOUSE; MUTANT MOUSE STRAIN; PATHOLOGY; PHYSIOLOGY; RNA INTERFERENCE; SCID MOUSE; THERAPEUTIC USE; TUMOR CELL LINE; TUMOR ESCAPE;

ADENOCARCINOMA; ANIMALS; ANTIGENS, CD59; CELL LINE, TUMOR; CETUXIMAB; COMPLEMENT ACTIVATION; COMPLEMENT MEMBRANE ATTACK COMPLEX; CYTOTOXICITY, IMMUNOLOGIC; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC VECTORS; HUMANS; LUNG NEOPLASMS; MALE; MICE; MICE, MUTANT STRAINS; MICE, SCID; NEOPLASM PROTEINS; PROMOTER REGIONS, GENETIC; PROTEINS; RNA INTERFERENCE; RNA, MESSENGER; RNA, NEOPLASM; RNA, SMALL INTERFERING; SMAD3 PROTEIN; TRANSCRIPTOME; TRANSFORMING GROWTH FACTOR BETA; TUMOR ESCAPE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84935439122     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2015.258     Document Type: Article

References (38)

1. Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol 2014; 15: 178-196
2. Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, Ting DT, et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 2013; 339: 580-584
3. Thiery JP, Sleeman JP. Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 2006; 7: 131-142
4. Tarin D, Thompson EW, Newgreen DF. The fallacy of epithelial mesenchymal transition in neoplasia. Cancer Res 2005; 65: 5996-6000 discussion 00-1
5. Zavadil J, Haley J, Kalluri R, Muthuswamy SK, Thompson E. Epithelialmesenchymal transition. Cancer Res 2008; 68: 9574-9577
6. Zavadil J, Bottinger EP. TGF-beta and epithelial-to-mesenchymal transitions. Oncogene 2005; 24: 5764-5774
7. Kim WS, Park C, Jung YS, Kim HS, Han J, Park CH, et al. Reduced transforming growth factor-beta type II receptor (TGF-beta RII) expression in adenocarcinoma of the lung. Anticancer Res 1999; 19: 301-306
8. Kong F, Jirtle RL, Huang DH, Clough RW, Anscher MS. Plasma transforming growth factor-beta1 level before radiotherapy correlates with long term outcome of patients with lung carcinoma. Cancer 1999; 86: 1712-1719
9. Keshamouni VG, Michailidis G, Grasso CS, Anthwal S, Strahler JR, Walker A, et al. Differential protein expression profiling by iTRAQ-2DLC-MS/MS of lung cancer cells undergoing epithelial-mesenchymal transition reveals a migratory/invasive phenotype. J Proteome Res 2006; 5: 1143-1154
10. Reka AK, Kuick R, Kurapati H, Standiford TJ, Omenn GS, Keshamouni VG. Identifying inhibitors of epithelial-mesenchymal transition by connectivity mapbased systems approach. J Thorac Oncol 2011; 6: 1784-1792
11. Reka AK, Kurapati H, Narala VR, Bommer G, Chen J, Standiford TJ, et al. Peroxisome proliferator-activated receptor-gamma activation inhibits tumor metastasis by antagonizing Smad3-mediated epithelial-mesenchymal transition. Mol Cancer Ther 2010; 9: 3221-3232
12. Reka AK, Chen G, Jones RC, Amunugama R, Kim S, Karnovsky A, et al. Epithelialmesenchymal transition-associated secretory phenotype predicts survival in lung cancer patients. Carcinogenesis 2014; 35: 1292-1300
13. Walport MJ. Complement. First of two parts. N Engl J Med 2001; 344: 1058-1066
14. Fishelson Z, Donin N, Zell S, Schultz S, Kirschfink M. Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors. Mol Immunol 2003; 40: 109-123
15. Jurianz K, Ziegler S, Garcia-Schuler H, Kraus S, Bohana-Kashtan O, Fishelson Z, et al. Complement resistance of tumor cells: basal and induced mechanisms. Mol Immunol 1999; 36: 929-939
16. Varsano S, Rashkovsky L, Shapiro H, Ophir D, Mark-Bentankur T. Human lung cancer cell lines express cell membrane complement inhibitory proteins and are extremely resistant to complement-mediated lysis; a comparison with normal human respiratory epithelium in vitro, and an insight into mechanism(s) of resistance. Clin Exp Immunol 1998; 113: 173-182
17. Donin N, Jurianz K, Ziporen L, Schultz S, Kirschfink M, Fishelson Z. Complement resistance of human carcinoma cells depends on membrane regulatory proteins, protein kinases and sialic acid. Clin Exp Immunol 2003; 131: 254-263
18. Kim DD, Song WC. Membrane complement regulatory proteins. Clin Immunol 2006; 118: 127-136
19. Yan J, Allendorf DJ, Li B, Yan R, Hansen R, Donev R. The role of membrane complement regulatory proteins in cancer immunotherapy. Adv Exp Med Biol 2008; 632: 159-174
20. Watson NF, Durrant LG, Madjd Z, Ellis IO, Scholefield JH, Spendlove I. Expression of the membrane complement regulatory protein CD59 (protectin) is associated with reduced survival in colorectal cancer patients. Cancer Immunol Immunother 2006; 55: 973-980
21. Xu C, Jung M, Burkhardt M, Stephan C, Schnorr D, Loening S, et al. Increased CD59 protein expression predicts a PSA relapse in patients after radical prostatectomy. Prostate 2005; 62: 224-232
22. Nishioka K, Kawamura K, Hirayama T, Kawashima T, Shimada K. The complement system in tumor immunity: significance of elevated levels of complement in tumor bearing hosts. Ann N Y Acad Sci 1976; 276: 303-315
23. Keshamouni VG, Jagtap P, Michailidis G, Strahler JR, Kuick R, Reka AK, et al. Temporal quantitative proteomics by iTRAQ 2D-LC-MS/MS and corresponding mRNA expression analysis identify post-transcriptional modulation of actincytoskeleton regulators during TGF-beta-Induced epithelial-mesenchymal transition. J Proteome Res 2009; 8: 35-47
24. Corrales L, Ajona D, Rafail S, Lasarte JJ, Riezu-Boj JI, Lambris JD, et al. Anaphylatoxin C5a creates a favorable microenvironment for lung cancer progression. J Immunol 2012; 189: 4674-4683
25. Masszi A, Fan L, Rosivall L, McCulloch CA, Rotstein OD, Mucsi I, et al. Integrity of cell-cell contacts is a critical regulator of TGF-beta 1-induced epithelial-tomyofibroblast transition: role for beta-catenin. Am J Pathol 2004; 165: 1955-1967
26. Hsu YF, Ajona D, Corrales L, Lopez-Picazo JM, Gurpide A, Montuenga LM, et al. Complement activation mediates cetuximab inhibition of non-small cell lung cancer tumor growth in vivo. Mol Cancer 2010; 9: 139
27. Thomson S, Buck E, Petti F, Griffin G, Brown E, Ramnarine N, et al. Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res 2005; 65: 9455-9462
28. Kohler BA, Ward E, McCarthy BJ, Schymura MJ, Ries LA, Eheman C, et al. Annual report to the nation on the status of cancer, 1975-2007, featuring tumors of the brain and other nervous system. J Natl Cancer Inst 2011; 103: 714-736
29. Kalluri R. EMT: when epithelial cells decide to become mesenchymal-like cells. J Clin Invest 2009; 119: 1417-1419
30. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009; 119: 1420-1428
31. Pasch MC, Bos JD, Daha MR, Asghar SS. Transforming growth factor-beta isoforms regulate the surface expression of membrane cofactor protein (CD46) and CD59 on human keratinocytes [corrected]. Eur J Immunol 1999; 29: 100-108
32. Jurianz K, Maslak S, Garcia-Schuler H, Fishelson Z, Kirschfink M. Neutralization of complement regulatory proteins augments lysis of breast carcinoma cells targeted with rhumAb anti-HER2. Immunopharmacology 1999; 42: 209-218
33. Zhao WP, Zhu B, Duan YZ, Chen ZT. Neutralization of complement regulatory proteins CD55 and CD59 augments therapeutic effect of herceptin against lung carcinoma cells. Oncol Rep 2009; 21: 1405-1411
34. Hu W, Ge X, You T, Xu T, Zhang J, Wu G, et al. Human CD59 inhibitor sensitizes rituximab-resistant lymphoma cells to complement-mediated cytolysis. Cancer Res 2011; 71: 2298-2307
35. Ge X, Wu L, Hu W, Fernandes S, Wang C, Li X, et al. rILYd4, a human CD59 inhibitor, enhances complement-dependent cytotoxicity of ofatumumab against rituximabresistant B-cell lymphoma cells and chronic lymphocytic leukemia. Clin Cancer Res 2011; 17: 6702-6711
36. Markiewski MM, Lambris JD. Is complement good or bad for cancer patients? A new perspective on an old dilemma. Trends Immunol 2009; 30: 286-292
37. Markiewski MM, DeAngelis RA, Benencia F, Ricklin-Lichtsteiner SK, Koutoulaki A, Gerard C, et al. Modulation of the antitumor immune response by complement. Nat Immunol 2008; 9: 1225-1235
38. Cragg MS, Howatt WJ, Bloodworth L, Anderson VA, Morgan BP, Glennie MJ. Complement mediated cell death is associated with DNA fragmentation. Cell Death Differ 2000; 7: 48-58